Paul Tudor Jones Biotechnology

Tudor Investment Corp Et Al

$26.8 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
REGN Regeneron Pharmaceuticals, Inc.	$72.4B	$39.6 Million 0.15% of portfolio	37,651	Q3 2024 New
RPRX Royalty Pharma PLC	$13.6B	$14.4 Million 0.05% of portfolio	508,753	Q3 2024 Added 62.8%
MRNA Moderna, Inc.	$16.2B	$10.2 Million 0.04% of portfolio	153,098	Q3 2024 Added 23.13%
BMRN Biomarin Pharmaceutical Inc	$11.5B	$6.52 Million 0.02% of portfolio	92,768	Q3 2024 New
ASND Ascendis Pharma A/S	$7.15B	$3.87 Million 0.01% of portfolio	25,891	Q3 2024 Reduced 22.42%
UTHR United Therapeutics Corp	$16.9B	$3.35 Million 0.01% of portfolio	9,346	Q3 2024 New
EXEL Exelixis, Inc.	$10.4B	$3.29 Million 0.01% of portfolio	126,836	Q3 2024 Reduced 12.89%
RARE Ultragenyx Pharmaceutical Inc.	$3.09B	$3.03 Million 0.01% of portfolio	54,496	Q3 2024 Added 57.67%
ADPT Adaptive Biotechnologies Corp	$1.14B	$2.64 Million 0.01% of portfolio	515,772	Q3 2024 Added 0.08%
AXSM Axsome Therapeutics, Inc.	$4.42B	$2.32 Million 0.01% of portfolio	25,832	Q3 2024 Added 36.08%
CRSP Crispr Therapeutics Ag	$3.39B	$2.21 Million 0.01% of portfolio	46,999	Q3 2024 New
IONS Ionis Pharmaceuticals Inc	$4.93B	$2.14 Million 0.01% of portfolio	53,479	Q3 2024 Added 308.3%
APLS Apellis Pharmaceuticals, Inc.	$3.3B	$2.11 Million 0.01% of portfolio	73,002	Q3 2024 New
IOVA Iovance Biotherapeutics, Inc.	$986M	$2.06 Million 0.01% of portfolio	218,927	Q3 2024 Reduced 27.0%
INCY Incyte Corp	$16.1B	$1.82 Million 0.01% of portfolio	27,474	Q3 2024 Added 29.06%
DYN Dyne Therapeutics, Inc.	$710M	$1.81 Million 0.01% of portfolio	50,483	Q3 2024 Added 7.25%
RVMD Revolution Medicines, Inc.	$3.59B	$1.74 Million 0.01% of portfolio	38,306	Q3 2024 New
NVO Novo Nordisk A S	$199B	$1.69 Million 0.01% of portfolio	14,227	Q3 2024 New
MLTX Moon Lake Immunotherapeutics	$1.69B	$1.61 Million 0.01% of portfolio	31,840	Q3 2024 Added 17.18%
FOLD Amicus Therapeutics, Inc.	$2.7B	$1.58 Million 0.01% of portfolio	148,354	Q3 2024 New
TBPH Theravance Biopharma, Inc.	$699M	$1.58 Million 0.01% of portfolio	196,578	Q3 2024 Added 1.45%
KYMR Kymera Therapeutics, Inc.	$2.43B	$1.52 Million 0.01% of portfolio	32,162	Q3 2024 New
XERS Xeris Biopharma Holdings, Inc.	$479M	$1.45 Million 0.01% of portfolio	507,357	Q3 2024 Reduced 11.48%
XENE Xenon Pharmaceuticals Inc.	$2.49B	$1.44 Million 0.01% of portfolio	36,687	Q3 2024 Added 45.4%
ACAD Acadia Pharmaceuticals Inc	$3.02B	$1.44 Million 0.01% of portfolio	93,404	Q3 2024 Reduced 8.4%
PTCT Ptc Therapeutics, Inc.	$3.32B	$1.43 Million 0.01% of portfolio	38,646	Q3 2024 Reduced 27.3%
VCYT Veracyte, Inc.	$3.14B	$1.39 Million 0.01% of portfolio	40,873	Q3 2024 Added 5.12%
ARWR Arrowhead Pharmaceuticals, Inc.	$2.2B	$1.21 Million 0.0% of portfolio	62,424	Q3 2024 New
KROS Keros Therapeutics, Inc.	$305M	$1.15 Million 0.0% of portfolio	19,787	Q3 2024 Added 91.05%
VERA Vera Therapeutics, Inc.	$915M	$1.08 Million 0.0% of portfolio	24,478	Q3 2024 New
AKRO Akero Therapeutics, Inc.	$1.21B	$993,000 0.0% of portfolio	34,634	Q3 2024 Added 0.92%
EWTX Edgewise Therapeutics, Inc.	$1.79B	$950,000 0.0% of portfolio	35,613	Q3 2024 Added 34.85%
ALNY Alnylam Pharmaceuticals, Inc.	$34.3B	$931,000 0.0% of portfolio	3,386	Q3 2024 Reduced 94.39%
MNKD Mannkind Corp	$1.55B	$894,000 0.0% of portfolio	142,469	Q3 2024 Added 4.84%
INSM Insmed Inc	$10.6B	$867,000 0.0% of portfolio	11,886	Q3 2024 New
VRDN Viridian Therapeutics, Inc.\De	$739M	$847,000 0.0% of portfolio	37,261	Q3 2024 New
SNDX Syndax Pharmaceuticals Inc	$806M	$829,000 0.0% of portfolio	43,070	Q3 2024 Reduced 8.66%
BEAM Beam Therapeutics Inc.	$1.83B	$804,000 0.0% of portfolio	32,817	Q3 2024 Reduced 33.06%
DAWN Day One Biopharmaceuticals, Inc.	$897M	$767,000 0.0% of portfolio	55,122	Q3 2024 Added 6.23%
XNCR Xencor Inc	$1.17B	$701,000 0.0% of portfolio	34,894	Q3 2024 Added 13.39%
RCUS Arcus Biosciences, Inc.	$950M	$697,000 0.0% of portfolio	45,650	Q3 2024 New
PHAT Phathom Pharmaceuticals, Inc.	$272M	$657,000 0.0% of portfolio	36,383	Q3 2024 New
LBPH Longboard Pharmaceuticals, Inc.	$815M	$630,000 0.0% of portfolio	18,925	Q3 2024 New
PTGX Protagonist Therapeutics, Inc	$1.85B	$622,000 0.0% of portfolio	13,858	Q3 2024 New
TYRA Tyra Biosciences, Inc.	$679M	$619,000 0.0% of portfolio	26,346	Q3 2024 New
INVA Innoviva, Inc.	$1.3B	$614,000 0.0% of portfolio	31,835	Q3 2024 New
RLAY Relay Therapeutics, Inc.	$583M	$571,000 0.0% of portfolio	80,683	Q3 2024 Added 21.97%
TVTX Travere Therapeutics, Inc.	$1.3B	$533,000 0.0% of portfolio	38,144	Q3 2024 Added 2.31%
VIR Vir Biotechnology, Inc.	$1.41B	$510,000 0.0% of portfolio	68,113	Q3 2024 Added 0.31%
NTLA Intellia Therapeutics, Inc.	$835M	$509,000 0.0% of portfolio	24,803	Q3 2024 Reduced 59.85%

Shares Options

Paul Tudor Jones

Paul Tudor Jones is the founder and CEO of Tudor Investment Corp, a successful investment firm that focuses on macro investing. Jones is known for his expertise in macro investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track Paul Tudor Jones's portfolio

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account